MOZART THERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 12 Feb 2026)
What this means for you
Not registered yet, but its 25 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97518221
- Mark type
- Stylized text
- Filed
- 25 Jul 2022
- Published for opposition
- 13 Aug 2024
- Attorney of record
- Connie Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products and preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, infectious diseases and disorders, cancer, and gastrointestinal diseases and disorders; biological products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; cell therapy products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; therapeutic products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; pharmaceutical products and preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; biological products, namely, preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; cell therapy products, namely preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; therapeutic and medicinal products, namely, preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; diagnostic biomarker reagents for use in diagnosing, preventing, and treating diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, and cancer; diagnostic agents, preparations, and substances for use in diagnosing, preventing, and treating diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, infectious diseases and disorders, cancer, and gastrointestinal diseases and disorders
Owner
- Mozart Therapeutics, Inc., Seattle, WA, US
- Mozart Therapeutics, Inc., Seattle, WA, US
Prosecution history
- 13 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Feb 2026 — SOU EXTENSION 3 GRANTED
- 12 Feb 2026 — SOU EXTENSION 3 FILED
- 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2025 — SOU EXTENSION 2 GRANTED
- 09 Sept 2025 — SOU EXTENSION 2 FILED
- 09 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Mar 2025 — SOU EXTENSION 1 GRANTED
- 26 Mar 2025 — SOU EXTENSION 1 FILED
- 26 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Aug 2024 — PUBLISHED FOR OPPOSITION